Evidence map›Paper›PMID 35842662›Full record

ArticleJournal of nanobiotechnology2022

Artificial stem cells mediated inflammation-tropic delivery of antiviral drugs for pneumonia treatment.

Aiping Qin, Sheng Chen, Songpei Li, Qizhen Li, Xiaotao Huang, Luoxing Xia, Yinshan Lin, Ao Shen, Andy Peng Xiang, Lingmin Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Aiping Qin *Key Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Sheng Chen *Key Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Songpei Li *Key Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Qizhen LiDepartment of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, Guangdong, China.
Xiaotao HuangKey Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Luoxing XiaKey Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Yinshan LinKey Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Ao ShenKey Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China. shenao@gzhmu.edu.cn.
Andy Peng XiangCenter for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou, 510080, China. xiangp@mail.sysu.edu.cn.
Lingmin ZhangKey Laboratory of Molecular Target and Clinical Pharmacology and the State and NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Third and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China. zhanglm@gzhmu.edu.cn.ORCID http://orcid.org/0000-0002-4215-5401
Guangzhou Medical University · CNState Key Laboratory of Respiratory Disease · CNSouthern University of Science and Technology · CNSun Yat-sen University · CN

Funding

Basic and Applied Basic Research Project of Guangzhou 02080390Guangzhou Medical University Outstanding Youth Development Program of Guangzhou Medical UniversityNational Natural Science Foundation of China 81700382National Natural Science Foundation of China 81870142National Natural Science Foundation of China 82070406National Natural Science Foundation of China 82072047National Natural Science Foundation of China 82170008Natural Science Foundation of Guangdong Province 2019A1515012166Natural Science Foundation of Guangdong Province 2020A1515011158Research Foundation of Education Bureau of Guangdong Province 2021ZDZX2004
6 · The paper itself

Abstract

backgroundCytomegalovirus (CMV) pneumonia is a major cause of morbidity and mortality in immunodeficiency individuals, including transplant recipients and Acquired Immune Deficiency Syndrome patients. Antiviral drugs ganciclovir (GCV) and phosphonoformate (PFA) are first-line agents for pneumonia caused by herpesvirus infection. However, the therapy suffers from various limitations such as low efficiency, drug resistance, toxicity, and lack of specificity.

methodsThe antiviral drugs GCV and PFA were loaded into the pH-responsive nanoparticles fabricated by poly(lactic-co-glycolic acid) (PLGA) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and further coated with cell membranes derived from bone marrow mesenchymal stem cells to form artificial stem cells, namely MPDGP. We evaluated the viral suppression effects of MPDGP in vitro and in vivo.

resultsMPDGP showed significant inflammation tropism and efficient suppression of viral replication and virus infection-associated inflammation in the CMV-induced pneumonia model. The synergistic effects of the combination of viral DNA elongation inhibitor GCV and viral DNA polymerase inhibitor PFA on suppressing the inflammation efficiently.

conclusionThe present study develops a novel therapeutic intervention using artificial stem cells to deliver antiviral drugs at inflammatory sites, which shows great potential for the targeted treatment of pneumonia. To our best knowledge, we are the first to fabricate this kind of artificial stem cell to deliver antiviral drugs for pneumonia treatment.

Indexed as

Antiviral AgentsNanoparticle Drug Delivery SystemCytomegalovirusCytomegalovirus InfectionsFatty Acids, MonounsaturatedFoscarnetGanciclovirHumansInflammationPneumoniaPolylactic Acid-Polyglycolic Acid CopolymerQuaternary Ammonium CompoundsStem Cells1,2-dioleoyloxy-3-(trimethylammonium)propaneAntiviral AgentsFatty Acids, MonounsaturatedFoscarnetGanciclovirNanoparticle Drug Delivery SystemPolylactic Acid-Polyglycolic Acid CopolymerQuaternary Ammonium CompoundsAntiviral drugsArtificial stem cellsCytomegalovirusInflammation-tropic deliveryPneumonia

Identifiers

PMID35842662
PMCPMC9287715
OpenAlexW4285586731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.